EW LAWSUIT UPDATE: Edwards Lifesciences Corporation Investors are Notified of Imminent December 13 Legal Deadline; Contact BFA Law if You Lost Money (NYSE:EW)

Group 1 - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] - The lawsuit alleges that Edwards Lifesciences misrepresented the demand and growth potential of its Transcatheter Aortic Valve Replacement (TAVR) platform, claiming that patient activation activities were ineffective and that healthcare organizations prioritized other treatments [2][3] - Following a significant reduction in TAVR guidance and disappointing financial results announced on July 24, 2024, Edwards' stock price dropped by 31%, from $86.95 to $59.70 per share [3] Group 2 - Investors in Edwards Lifesciences are encouraged to seek legal options and submit their information to the law firm representing the case, with no upfront costs for shareholders [4] - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and has achieved notable recoveries in past cases, including over $900 million from Tesla, Inc. [4]